- Ophthotech - A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.
- Wet AMD (treatment naive, newly diagnosed lesion)
- Fovista (Ophthotech): Fovista combined with Lucentis versus Lucentis monotherapy to assess efficacy in CNVM regression
- DARPin (Allergan): Apicipar intravitreal injection every 3 months versus monthly Lucentis intravitreal injection monotherapy
- Squalamine (OHR): Phase 3 topical squalamine eye drop for treatment-naive wet AMD combined with Lucentis versus Lucentis monotherapy
- Wet AMD (for patients currently undergoing treatment with injection therapy) - Encapsulated Cell Technology / Anti-VEGF drug eluting implant (Neurotech): Surgical implantation of cells designed to produce therapeutic levels of intravitreal Eylea for 2 years. Patients currently undergoing monthly intravitreal injection therapy can have a one-time surgical procedure which could potentially eliminate the need for future injections indefinitely.
- Central Retinal Vein Occlusion - SCORE-2 (National Eye Institute): Comparative study of intravitreal Eylea versus Avastin for treatment of macular edema due to HRVO or CRVO.
